A phase II trial of RX 0201 as a second-line therapy in patients with advanced renal cell cancer.

Trial Profile

A phase II trial of RX 0201 as a second-line therapy in patients with advanced renal cell cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2009

At a glance

  • Drugs RX 0201 (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top